Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

<p>Abstract</p> <p>Background</p> <p>Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor...

Full description

Bibliographic Details
Main Authors: Minegishi Yuji, Okano Tetsuya, Matsuda Kuniko, Kataoka Kiyoko, Seike Masahiro, Chen Mingwei, Kokubo Yutaka, Kosaihira Seiji, Gemma Akihiko, Noro Rintaro, Yoshimura Akinobu, Kudoh Shoji
Format: Article
Language:English
Published: BMC 2006-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/6/277

Internet

http://www.biomedcentral.com/1471-2407/6/277

Similar Items